IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation turns positive

Q3 FY2026 stock-based compensation was $0, compared with -$44.08M a year earlier. Trailing-twelve-month stock-based compensation was $33.34M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $8.34M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$33.34M+133.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 stock-based compensation of $33.34M is the 4th largest of the 5 companies compared; the peer median is $86M.
  • Its year-over-year change of +133.8% is the highest of 5, against a peer median of +13.7%.
  • Stock-based compensation amounts to 0.7% of revenue for IDXX, versus a peer median of 1.3%.
IDXX Competitors Peer median
Stock-Based Compensation for IDXX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$892M +12.5%—1.3%
ZTSZoetis Inc.LTM Jun 2026$95M +25.0%+10.2%1.0%
ELANElanco Animal Health IncorporatedLTM Sep 2026$77M +14.9%+4.8%1.5%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$33.34M +133.8%—0.7%
NEOGNeogen CorporationLTM Aug 2026$11.54M -36.9%+9.6%1.3%
Peer median (excluding IDXX) $86M+13.7%+9.6%1.3%

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income744.84M679.09M845.04M887.87M1.06B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
Deferred Income Tax(3.38M)(35.07M)(48.31M)(24.19M)131.2M
Stock-Based Compensation37.76M49.77M59.74M60.3M0
Change in Working Capital(137.52M)(273.53M)(72.43M)(133.24M)(227.51M)
Accounts Receivables(33.14M)(41.4M)(53.87M)(28.28M)(68.72M)
Inventory(52.92M)(121.73M)(28.65M)(28M)(789K)
Accounts Payables11.23M3.47M(557K)8.09M(8.57M)
Other Working Capital(62.7M)(113.87M)10.65M(85.04M)(149.43M)
Other Non-Cash Items9.25M10.82M7.56M8.34M69.73M
Operating Cash Flow755.55M542.98M906.51M929M1.18B
Capital Expenditures(119.55M)(148.84M)(133.63M)(130.92M)(124.68M)
Acquisitions (Net)(173.42M)(46.51M)0(77.7M)0
Purchases of Investments0(25M)00(756K)
Sales of Investments071.51M01.56M0
Other Investing Activities0(46.51M)8.38M(10M)2.74M
Investing Cash Flow(292.97M)(195.35M)(125.25M)(207.06M)(136.24M)
Debt Repayment23.5M430.5M(404M)(75M)(30.39M)
Common Stock Issued46.57M35.75M47.03M44.49M93.36M
Common Stock Repurchased(746.78M)(819.71M)(71.92M)(837.03M)(1.22B)
Dividends Paid00000
Other Financing Activities(20.7M)(17.04M)(13.11M)(10.53M)(7.24M)
Financing Cash Flow(697.41M)(370.94M)(442M)(878.07M)(1.16B)
Effect of Forex Changes(4.64M)(8.61M)2.13M(9.53M)11.2M
Net Change in Cash(239.47M)(31.91M)341.39M(165.67M)(108.2M)
Free Cash Flow636M394.15M772.88M798.08M1.05B

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.